Cannara Biotech Inc.
LOVE.V
TSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 63.93M | 60.02M | 56.76M | 54.15M | 49.04M |
| Total Other Revenue | 10.70K | 10.70K | -70.70K | -50.60K | 88.60K |
| Total Revenue | 63.94M | 60.03M | 56.69M | 54.10M | 48.98M |
| Cost of Revenue | 40.82M | 38.23M | 35.37M | 31.55M | 26.48M |
| Gross Profit | 23.12M | 21.79M | 21.32M | 22.55M | 22.50M |
| SG&A Expenses | 15.39M | 14.45M | 13.38M | 12.61M | 10.76M |
| Depreciation & Amortization | 913.90K | 1.01M | 740.00K | 756.50K | 794.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.92M | 54.52M | 50.37M | 45.73M | 38.79M |
| Operating Income | 6.02M | 5.51M | 6.32M | 8.36M | 10.19M |
| Income Before Tax | 3.90M | 3.24M | 3.94M | 4.61M | 6.72M |
| Income Tax Expenses | -898.00K | -1.43M | -- | -- | -- |
| Earnings from Continuing Operations | 4.80 | 4.66 | 3.94 | 4.61 | 6.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.80M | 4.66M | 3.94M | 4.61M | 6.72M |
| EBIT | 6.02M | 5.51M | 6.32M | 8.36M | 10.19M |
| EBITDA | 10.44M | 9.99M | 10.53M | 12.42M | 14.07M |
| EPS Basic | 0.05 | 0.05 | 0.04 | 0.05 | 0.07 |
| Normalized Basic EPS | 0.01 | 0.01 | 0.01 | 0.03 | 0.04 |
| EPS Diluted | 0.05 | 0.04 | 0.04 | 0.04 | 0.07 |
| Normalized Diluted EPS | 0.01 | 0.01 | 0.01 | 0.03 | 0.04 |
| Average Basic Shares Outstanding | 360.08M | 360.28M | 362.90M | 363.55M | 361.88M |
| Average Diluted Shares Outstanding | 364.64M | 364.08M | 365.19M | 365.07M | 363.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |